Subsequently, a similar metabolic association was observed with high‐grade serous ovarian tumors positive for the mutational signature 3: higher OXPHOS gene expression in S3+, HR‐defective tumors (false‐discovery rate [FDR]‐adjusted P = 0.025, Fig 1B, top panel) and with BRCA1/2 mutation status of TCGA ovarian cancer datasets (P < 0.001, Fig 1B, middle panel). This evidence concerns the gene BRCA1 and ovarian cancer.